Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984502 · ClinicalTrials.gov registry record · Phase 1
CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01984502 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT01984502, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The feasibility of reducing fractions in early-stage laryngeal cancer has not previously been prospectively studied, and we will therefore conduct a careful phase I bio-equivalent dose fraction reduction study.
Interventions
- RADIATION CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-11-18 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984502
The ClinicalTrials.gov registry entry for NCT01984502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy is the first listed.
NCT01984502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984502 about?
NCT01984502 is a clinical study titled "CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer". The feasibility of reducing fractions in early-stage laryngeal cancer has not previously been prospectively studied, and we will therefore conduct a careful phase I bio-equivalent dose fraction reduction study.
What is the current status of trial NCT01984502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-11-18. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT01984502?
The interventions under investigation include: CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT01984502?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.